Common stock, $0.001 Par Value
- Symbol
- ORKA
- Exchange
- NASDAQ
- Classification
- COMMON
- Status
- Current
Current Report · Items 2.02, 9.01 · 8-K
Oruka Therapeutics, Inc.
ORKANASDAQEQUITYCurrent
Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition. On August 10, 2026, Oruka Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the second quarter ended June 30, 2026. A copy of the press release is furnished as Exhibit 99.1 to this report.…
Press release in this filing
Oruka Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update →Company context
Oruka Therapeutics is developing novel biologics designed to set a new standard for the treatment of chronic skin diseases. Oruka’s mission is to offer patients suffering from inflammatory diseases like plaque psoriasis and hidradenitis suppurativa the greatest possible freedom from their condition by achieving high rates of disease clearance with dosing as infrequently as once or twice a year. For more information, visit www.orukatx.com and follow Oruka on LinkedIn.
Current securities
Registered securities in this filing
Oruka Therapeutics, Inc. · 8-K · Filed 2026-08-10
Disclosure sections
Item 2.02Item 2.02 - Results of Operations
Item 2.02
Results of Operations and Financial Condition.
On August 10, 2026, Oruka
Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the second quarter ended June
30, 2026. A copy of the press release is furnished as Exhibit 99.1 to this report.
The information in this Item
2.02, including Exhibit 99.1 to this report, shall not be deemed to be “filed” for purposes of Section 18 of the Securities
Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall
it be deemed incorporated by reference into any filing under the Exchange Act or under the Securities Act of 1933, as amended, except
as shall be expressly set forth by specific reference in such filing.
Filed exhibits (1)
EX-99.1 2 ea030131201ex99-1.htm PRESS RELEASE, DATED AUGUST 10, 2026 Exhibit 99.1 Oruka Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update EVERLAST-A Week 28 data expected at the end of 3Q 2026; 52-week data for all participants expected in December 2026 EVERLAST-B fully enrolled ahead of schedule, with Week 16 data now expected in 4Q 2026 Phase 3 program for ORKA-001 expected to begin in 1H 2027 ORCA-SURGE Week 16 data accelerated, now expected in 1Q 2027 ORCA-SPLASH, a Phase 2 trial of ORKA-002 in moderate-to-severe hidradenitis suppurativa, initiated ORKA-004, a novel half-life extended monoclonal antibody targeting TL1A, to enter the clinic in 4Q 2026 Cash, cash equivalents and marketable securities of $1.1 billion expected to fund the Company through a BLA filing for ORKA-001 MENLO PARK, Calif., Aug. 10, 2026 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a clinical-stage biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases including plaque psoriasis (PsO) and hidradenitis suppurativa (HS), today reported second quarter 2026 financial…
Open exhibit ↗